# US 2020/0392109 A1 · Crystalline forms and compositions of cftr modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392109 A1
- Document ID: US20200392109A1
- Status: Published application
- Kind: A1
- Application number: 16/829,765
- Filed: 2020-03-25
- Published: 2020-12-17
- Earliest claimed: 2017-10-19
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Varsha Dhamankar; Kirk Raymond Dinehart; Eleni Dokou; Lori Ann Ferris; Nishanth Gopinathan; Katie McCarty; Catherine Metzler; Beili Zhang; Samuel Moskowitz; Sarah Robertson; David Waltz; Eric L. Haseltine; Weichao George Chen
- Web page: https://patentgrep.com/patent/US20200392109A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K 9/10: Dispersions; Emulsions
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

## Claims

### Claim at position 1

-7. (canceled)

### Claim 8

A method of preparing a crystalline form of Compound I: selected from:
a) preparing crystalline Form C of a potassium salt/co-crystal of Compound I, comprising stirring a potassium salt of Compound I with a solvent system comprising at least one source of water;
b) preparing crystalline Form A of a sodium salt of Compound I, comprising reacting Compound I with a sodium base;
c) preparing crystalline Form D of a sodium salt Compound I, comprising heating a crystalline Form M or Form E of a sodium salt of Compound I at a temperature in a range from 280° C. to 300° C. under anhydrous conditions;
d) preparing crystalline Form M of a sodium salt of Compound I, comprising reacting Compound I with a sodium base in methanol;
e) preparing crystalline Form A of Compound I, comprising de-solvating at least one solvate of Compound I chosen from ethanol solvates of Compound I and methanol solvates of Compound I;
f) preparing crystalline Form E of a sodium salt of Compound I, comprising reacting Compound I with a sodium base in ethanol; and
g) preparing crystalline Form H of a sodium salt of Compound I, comprising de-solvating crystalline Form M or Form E of a sodium salt of Compound I or crystalline Form E of a sodium salt of Compound I in the presence of one source of water.

### Claim at position 3

-28. (canceled)
